Niban Activators
Niban activators are a diverse group of chemical compounds that can enhance the functional activity of the protein Niban, primarily through their influence on the ERK signaling pathway. These compounds can either directly stimulate the ERK pathway or indirectly enhance ERK signaling by inhibiting other competing pathways. EGF, a potent activator of EGFR, triggers the ERK pathway and subsequently enhances the function of Niban. SB203580 and LY294002, inhibitors of p38 MAPK and PI3K respectively, can enhance ERK signaling by reducing competition for shared signaling intermediates or instigating compensatory mechanisms, which ultimately boosts the functional activity of Niban.
Another class of Niban activators includes compounds which can increase intracellular cAMP levels and hence indirectly influence the ERK pathway. Elevated cAMP levels can potentiate ERK signaling through various mechanisms, such as the activation of Rap1 or the inhibition of RKIP, leading to an enhanced functional state of Niban. Further, Anisomycin and SP600125, a JNK activator and inhibitor respectively, can affect the ERK pathway through crosstalk mechanisms, resulting in enhanced Niban activity. Finally, Y-27632 and H-89, inhibitors of ROCK and PKA respectively, can enhance ERK signaling through compensatory mechanisms, further bolstering Niban's functional activity. These compounds underscore the intricate network of cellular signaling pathways and their interplay in regulating the function of proteins like Niban.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective and cell-permeable inhibitor of MEK, an upstream activator of ERK. By inhibiting MEK, PD98059 can cause a compensatory increase in ERK signaling, which can enhance the functional activity of Niban without impacting its expression levels. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, this compound can increase the relative signaling through the ERK pathway, which can enhance the functional activity of Niban. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K inhibition can lead to enhanced signaling through the ERK pathway, which can enhance the functional activity of Niban. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin is an activator of adenylate cyclase, which increases intracellular cAMP levels. Elevated cAMP can enhance ERK signaling, which can enhance the functional activity of Niban. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a phosphodiesterase inhibitor that raises intracellular cAMP levels. This can enhance ERK signaling, resulting in enhanced functional activity of Niban. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a JNK activator, and crosstalk between the JNK and ERK pathways can result in enhanced ERK signaling, which can enhance the functional activity of Niban. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective JNK inhibitor. Inhibiting JNK can lead to enhanced signaling through the ERK pathway, which can enhance the functional activity of Niban. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 5 g 100 g 250 g 1 kg 5 kg | $32.00 $66.00 $95.00 $188.00 $760.00 | 13 | |
Caffeine is a phosphodiesterase inhibitor that raises intracellular cAMP levels. This can enhance ERK signaling, which can enhance the functional activity of Niban. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK1 and ROCK2. Inhibition of ROCK can lead to a compensatory increase in ERK signaling, which can enhance the functional activity of Niban. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
H-89 is a potent PKA inhibitor. By inhibiting PKA, H-89 can lead to a compensatory increase in the ERK signaling pathway, which can enhance the functional activity of Niban. | ||||||